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Galectins are β-galcotosid-binding lectins. The function of galectins varies with their tissue-specific and subcellular location, and
their binding to carbohydrates makes them key players in several intra- and extracellular processes where they bind to
glycosylated proteins and lipids. In humans, there are 12 identified galectins, some with tissue-specific distribution. Galectins are
found inside cells and in the nucleus, cytosol, and organelles, as well as extracellularly. Galectin-1, -2, -3, -4, -7, -8, -9, and -12
can all induce T-cell apoptosis and modulate inflammation. In the context of metabolic control and loss of the same in, for
example, diabetes, galectin-1, -2, -3, -9, and -12 are especially interesting. This review presents information on galectins relevant
to the control of inflammation and metabolism and the potential to target galectins for therapeutic purposes.
1. Introduction
Saccharides are key energy molecules in metabolic pathways.
They are also used to modify proteins and lipids to make gly-
colipids and glycoproteins, that are important in intracellular
and extracellular processes. It is therefore not surprising that
lectins that bind sugar groups are important modulators of
many processes and key functional players in others.
Galectins are proteins that bind β-galactosides such as N-
acetyllactosamine present in N-linked and O-linked glyco-
proteins. They are involved in the control of, among others,
pre-mRNA splicing, and in the control of apoptosis, cell cycle,
cell division, metastasis, and diabetes [1–4]. They can bind to
and agglutinate bacteria, and some galectins can kill bacteria
directly without the activation of other factors, such as
complement factors [5, 6]. In humans, genes for galectin-1,
-2, -3, -4, -7, -8, -9, -10, -12, -13, -14, and -16 are found in
GenBank (https://www.ncbi.nlm.nih.gov/genbank/ version
19.12.2017, 23.30.00). Even if carbohydrate binding is the
classical galectin mode of action, galectins can also interact
with other proteins in a carbohydrate-independent manner
[7]. One or two galectin carbohydrate recognition domain(s)
(CRD(s)) is/are present in the galectins. In prototype
galectins (galectin-1, -2, -7, -10, -13, -14, and -16), the protein
consists of the globular CRD, the galectin fold with two beta
sheets. The chimera galectin-3 has a C-terminal CRD and
an N-terminal tail, whilst the tandem repeat galectins (galec-
tin-4, -8, -9, and -12) have two CRDs. Known galectin ligands
are, among others, CD45, CD7, CD43, CD2, CD3, CD4,
CD107, CEA, laminin and fibronectin, glycosaminoglycans,
integrins, GM1 ganglioside, polypeptide HBGp82, glycopro-
tein 90 K/MAC-2BP, CA125 cancer antigen, and pre-B cell
receptor (reviewed in [8]). Galectins can often be both nega-
tive and positive modulators of the same processes, suggest-
ing plasticity in isoforms, posttranslational modification(s)
or comolecules present, and/or differences in localization.
Processes such as inflammation and metabolism are
tightly regulated and fine-tuned. Lack of control can lead to
diseases such as diabetes; in fact, chronic, low-grade inflam-
mation is seen in obesity, and this inflammation can lead to
obesity-related insulin resistance and eventually type 2 diabe-
tes mellitus [9]. In diabetes mellitus, a long-standing hyper-
glycemic state can give production of advanced glycation
end products (AGEs) that bind to organic molecules and
cause complications [10]. In obesity, inflammation is
increased, and the number of activated (proinflammatory)
Hindawi
Mediators of Inflammation
Volume 2018, Article ID 9186940, 11 pages
https://doi.org/10.1155/2018/9186940
macrophages, associated with insulin resistance in human
obesity, increases in human fat tissues [11]. This accumula-
tion and activation of macrophages in turn change the
metabolism in white adipocytes, and obesity-related insulin
resistance can be looked upon as a disease promoted by
chronic inflammation in adipose tissues [12].
Galectin family members are molecules increasingly
focused upon as regulators of cellular processes including
metabolism and inflammation. This review will focus on
the roles of galectins in metabolism and inflammation to
elucidate if the galectins could be key regulators involved in
the linking of both processes. The reviews’ metabolism
control of galectin part will be centred on diabetes and
obesity, two processes where inflammation and metabolism
regulation are important both in the development of imbal-
ances and in upholding them.
2. Main Text
2.1. Galectin-1. Galectin-1 is a prototype galectin with one
carbohydrate recognition domain. It is, among others,
released from adipose tissues [13], stromal cells in the thy-
mus, lymph nodes, endothelial cells [14], and placenta cells
[15]. Apoptosis of activated (antigen-primed) T-cells is
induced by galectin-1 in a CD45-dependent manner [14],
and T-cell homeostasis can be regulated by galectin-1
through inhibition of clonal expansion and induction of apo-
ptosis. Activated T-cell apoptosis induced by galectin-1 is
caspase-8- and -9-dependent [16]. Interestingly, activated
T-cells themselves can produce galectin-1 through MEK1/
ERK, p38 MAP kinase, and p70S6 kinase signalling path-
ways, suggesting that this is an autocrine suicide mechanism
used to terminate an effector immune response [17]. On the
other hand, resting T-cells bind galectin-1, but apoptosis is
not induced [14]. Galectin-1 is anti-inflammatory, and its
mRNA is upregulated in the placenta in preeclampsia; this
is suggested to be a fetal response to maternal systemic infec-
tion [15]. The anti-inflammatory activity of galectin-1 can be
used to reduce allergic conjunctivitis, an inflammation of the
conjunctiva and other parts of the eye. In an allergic conjunc-
tivitis model in mice, externally administered recombinantly
produced galectin-1 was an inhibitor of allergic reaction.
Galectin-1 reduced IgE levels; however, this was only a slow-
ing of the IgE response as, at 24 hours, galectin-1-treated
mice had higher IgE levels than nontreated (allergy control)
mice had. In spite of the higher IgE levels, clinical signs were
reduced in galectin-1-treated mice [18].
Therapeutic administration of galectin-1 suppresses
T-cell-dependent chronic inflammation in arthritis [19],
in hepatitis [20], and in colitis [21], suggesting a broad
potential for therapeutic use in inflammatory diseases.
Interestingly, in type one diabetes, T-cell-mediated auto-
immunity destroys insulin-producing pancreatic β-cells.
This process can be inhibited by galectin-1 in vivo [17].
Galectin-1 is suggested to have a role in improving glucose
metabolism in obese people [22], and galectin-1 levels are
higher in obese children than in normal-weight children
[22]. Galectin-1 has a potential to be used as an inhibitor of
inflammation-related diseases such as diabetes, and also
inhibiting galectin-1 led to weight loss in diet-induced obese
mice, where weekly injections with a galectin-1 inhibitor
attenuated adipogenesis and lipogenesis and increased
expression of proteins associated with thermogenesis and
energy expenditure [23]. Hence, both stimulation and inhibi-
tion of galectin-1 can be of therapeutic value. Galectin-1
levels increase in eyes of patients with diabetes after accumu-
lation of AGEs, and vitreous aspirates from eyes of patients
with diabetic macular edema and later proliferative diabetic
retinopathy have increased galectin-1 levels. AGE production
induces IL-1β via ERK1/2, and PI3K signalling is involved in
galectin-1 induction in these patients [24]. This increase in
galectin-1 level could be a protective response to the
increased AGE levels, similar to that seen in kidneys where
galectin-3 is involved in clearance of AGEs [25].
2.2. Galectin-2. Galectin-2 is a prototype, single-CRD galec-
tin, primary expressed in the gastrointestinal tract which
can induce T-cell apoptosis through the caspase-3- and -9-
dependent intrinsic apoptotic pathway where, among others,
cytochrome c leaves the mitochondria. The apoptosis activa-
tion is independent of binding to the glycoprotein CD3 or
CD7 [16]. In the presence of galectin-2, activated T-cell pro-
files are modulated to be dominated by Th2 [16].
Interestingly, in a search for genes associated with insulin
resistance, a genotype of galectin-2, LGALS2 rs7291467, was
stronger associated with changed fasting plasma glucose and
serum insulin than other alleles were [26], and the same
genotype which has a single-nucleotide polymorphism
(3279C → T) in intron 1 of LGALS2 encoding galectin-2
was previously found to be significantly associated with myo-
cardial infarction [27]. Galectin-2 binds to the proinflamma-
tory cytokine lymphotoxin-α to regulate inflammation [27].
Galectin-2 is present in the pancreas, but not in islets—only
in exocrine cells [28]. It would be interesting to see if
galectin-2 present in the pancreas could influence inflam-
mation and the production of insulin in beta cells in the
nearby islet; however, we failed to find functional
galectin-2 studies on diabetes or obesity.
2.3. Galectin-3. Galectin-3 has several alternative names.
Galectin-3 was early characterised in the outer membrane
of macrophages and named Mac-2 antigen [29]; found to
be IgE binding and named εBP [30]; named CBP35,
carbohydrate-binding protein 35 from mouse 3T3 fibroblasts
[31]; and named CBP30 as baby hamster kidney
carbohydrate-binding protein [32].
Galectin-3 is the only chimera galectin; it has a C-
terminal carbohydrate recognition domain as well as an N-
terminal tail. Galectin-3 can, like galectin-1, induce T-cell
apoptosis [33]; the N-terminal end and the CRD coordinate
to induce signalling pathways leading to caspase-9 activation
[34]. Inhibiting the N-terminal end with an antibody shuts
down apoptosis stimulation [34]. When it comes to apopto-
sis, galectin-3 can be both antiapoptotic and proapoptotic.
The antiapoptotic effect is dependent on phosphorylation
of serine 6 in galectin-3 and the intracellular presence of
galectin-3 [35]; phosphorylated, but not unphosphorylated,
galectin-3 can be exported from the nucleus to the cytoplasm
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to act as an inhibitor of apoptosis by interacting with mito-
chondria to, among others, prevent cytochrome c release
and caspase-3 activation [36, 37].
The N-terminal and C-terminal ends can both be
involved in dimerization or possible oligomerisation of
galectin-3, thought to be important for the function of the
molecule [38, 39]. The binding properties of galectin-3 to
their ligands are pH-dependent [40]; this raises the possibil-
ity that pH could be a contributing factor in determining
galectin function in different locations including the cellular
microenvironments. This is a property exploited in cellular
sorting of galectin-3 in polarized Madin-Darby canine
kidney cells [41].
Regulation of galectin-3 binding to its ligands is modu-
lated by the phosphorylation state of serine in the N-
terminal of the protein, where phosphorylation decreases
binding and dephosphorylation increases binding [42].
Phosphorylation of tyrosine 107 can give the cleavage of
galectin-3, and the ratio of phosphorylated/dephosphory-
lated galectin-3 can be used for the prognosis of prostate can-
cer as well as be a target for potential treatment [43].
Galectin-3 can be endocytosed by macrophages. Uptake
of galectin-3 in classically activated M1 macrophages is
carbohydrate-independent and mediated by N-terminal end
binding, whilst uptake in alternatively activated M2 macro-
phages, as well as nonmacrophages, is carbohydrate-
dependent and involves the C-terminal CRD [44]. In T-cells,
galectin-3 is present at the cell surface associated with the
TCR complex; it seems to inhibit uncontrolled T-cell activa-
tion and potentiates downregulation of TCR in T-cells [45].
Galectin-3 is observed in among others fibroblasts, chondro-
cytes, osteoblasts, osteoclasts, keratinocytes, Schwann cells
and gastric mucosa. It is also found in endothelial cells in a
number of tissues, and in immune cells such as neutrophils,
eosinophils, basophils, mast cells, Langerhans cells and den-
dritic cells (cell types reviewed in [46]). It has a role in adipo-
cyte proliferation, and obese mice have more galectin-3 in
adipocytes than lean subjects have [47].
Interestingly, whilst galectin-1 can inhibit autoimmune
diseases, the research focus on galectin-3’s potential thera-
peutic use is in large focusing on inhibiting galectin-3. This
is because galectin-3 promotes cancer and metastasis [1],
and inhibition would hence have a great potential for thera-
peutic anticancer treatment.
Galectin-3 is however beneficial in other situations. It
binds AGEs, glycated proteins, and lipids formed, among
others, in diabetic patients, and galectin-3 knockout mice
have accelerated glomerulopathy and higher renal/glomeru-
lar AGEs levels, suggesting that galectin-3 is involved in
receptor pathways needed for AGE removal in kidneys
[25]. AGEs are interesting as their receptor-mediated uptake
led to cytokine production [48]. Galectin-3 can also be a
receptor for lipoxidation end products (ALEs) [49]. Even
if galectin-3 is beneficial to the kidney as AGE and ALE
binders and thus inhibits inflammation, its proinflamma-
tory effect can contribute to inflammation-produced kid-
ney damage [50, 51]. The proinflammatory galectin-3
property has been linked to cardiac inflammation in obese
patients [52] and to cardiac lipotoxicity (lipid deposits in
the heart) and subsequent mitochondrial dysfunction
affecting heart metabolism [53].
2.4. Galectin-4. Galectin-4 is a tandem-repeat galectin with
two CRDs joined by a linker. Its main expression is in the
gastrointestinal tract of healthy individuals where it has a role
in control of intestinal inflammation [54]. In the intestine,
galectin-4 interacts with activated T-cells through CD3 bind-
ing and promotes calpain-mediated T-cell apoptosis [54].
Importantly, it reduces proinflammatory cytokine produc-
tion in the intestine mucosa in a colitis model [54]. However,
it can also promote inflammation in the intestine by stimu-
lating CD4+ T-cells to produce IL-6 [55].
Taken together, this suggests that galectin-4 could be
important not only for ulcerative colitis but also for other
inflammatory bowel diseases such as Crohn’s disease.
Galectin-4 has anticancer properties and has been shown to
suppress colorectal cancer [56]; knockdown of it promotes
tumorigenesis, and lower levels of galectin-4 expression were
observed in inflamed precursor lesions of colorectal cancer
[57]. Since T-cell response can help remove cancer cells, the
fact that galectin-4 can promote mucosal T-cell apoptosis
and also suppress colorectal cancer seems counterintuitive
and suggests that there are mechanisms in colorectal inflam-
mation and cancer prevention that warrant further studies.
In addition, it is interesting that galectin-4 modulates inflam-
mation, but there seem to be no studies focused on diabetes
or other inflammation-dependent obesity diseases associated
with galectin-4, suggesting that galectin-4 is not involved in
modulation of metabolic diseases since it is mainly expressed
in the intestine.
2.5. Galectin-7. Galectin-7 is a homodimeric prototype galec-
tin with one CRD. It is mainly present in the epidermis [58]
and can induce apoptosis of stimulated T-cells in a manner
dependent upon caspase-1, -3, and -8, but not caspase-9
[16]. Galectin-7-deficient mice appear normal; however,
when exposed to UVB irradiation, apoptosis is induced
earlier and lasts longer than in wild-type mice [58]. This is
surprising, since galectin-7 is proapoptotic [16]; however,
the galectin-7-negative mice also show hyperproliferation of
cells after UVB irradiation and after wounding [58], more
in line with what one would expect when inhibiting the
expression of a proapoptotic protein. Overexpression of
galectin-7 in mice compromises the skin by leading to loss
of cell junctions and defective skin repair [59]. Galectin-7’s
predominant expression in the skin suggests that it would
not influence diabetes or obesity-related inflammation; how-
ever, one would suspect that it could play a role in skin
diseases related to flawed control of the immune system.
Hence, it is not surprising that, in the stratum corneum,
galectin-7 is highly expressed in atopic dermatitis patients
[60] and possible treatment of this and other skin diseases
could target galectin-7.
2.6. Galectin-8. Galectin-8 is a tandem-repeat galectin with
two CRDs joined by a linker [61]; it can exist in two splice
variants with different linker lengths [62]. Altogether, six
possible isoforms exist, three with two CRDs and three with
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one CRD [63]. Galectin-8 is expressed in the liver, kidney,
cardiac muscle, lung, and brain [61] as well as in a number
of different tumoral cells [63]. Galectin-8 induces apoptosis
in T-cells through the expression of the death factor
Fas ligand and gives caspase-mediated apoptosis [64].
Dimeric galectin-8 resulted in phosphatidylserine exposure
in the outer bilayer of cells, something which normally
happens during apoptosis activation; however, in the case
of galectin-stimulated phospholipid redistribution, this
occurred independently of apoptosis [65]. Galectin-8 is
secreted under basal conditions from human microvascular
endothelial cells and has an autocrine function in that
extracellular galectin-8 stimulates the secretion of
proinflammatory molecules, CXCL1 (GRO-α), GM-CSF,
IL-6, and CCL5 (RANTES), from the endothelial cells [66].
Platelets can also express galectin-8 and be activated by the
lectin in an N-terminal CRD-dependent manner [62].
Hence, both endothelial cells and platelets contribute to
inflammation stimulated by galectin-8. Galectin-8 can also
act proinflammatory by stimulating dendritic cells that
secrete proinflammatory cytokines and stimulate antigen-
specific T-cells [67]. Activation of neutrophils to produce
superoxide is also stimulated by galectin-8 [68]. Galectin-8
is clearly involved in regulation of the immune system;
however, we failed to find involvement of galectin-8 in diabe-
tes or other inflammation processes induced by obesity.
2.7. Galectin-9. Galectin-9 is a tandem-repeat galectin with
two CRDs joined by a linker sequence. It is expressed in the
liver, small intestine, and thymus and in a lesser amount in
the kidney, spleen, lung, and cardiac and skeletal muscle
and in a low amount in reticulocytes and brain [69].
Galectin-9 is involved in T-cell selection in the thymus
where it will induce apoptosis of CD4/CD8 double-negative
or double-positive thymocytes and further in promoting
naïve T-cell differentiation into Treg and by inhibiting naïve
T-cell differentiation into T-helper 17 cells. Finally, it is
involved through interaction with TIM3 (T-cell immuno-
globulin domain and mucin domain protein 3) in apoptosis
induction of CD4+ T-helper 1 (Th1) cells, Th17, cells and
CD8+ cytotoxic T-cells. TIM3-negative Th2 cells do not go
into apoptosis upon exposure to galectin-9, neither do
TIM3-positive Treg cells (T-cells and galectin-9 reviewed in
[70]). Taken together, this points to galectin-9 as an impor-
tant molecule in the regulation of the immune system; in
particular, the induction of apoptosis in Th1 and Th17 cells
is interesting as activation of these cells is key in regulation
of inflammation in, for example, autoimmune diseases. It
also suggests that there is a need for research to investigate
whether differential glycosylation of the cells can explain
why not all TIM3-positive cells enter apoptosis when
exposed to galectin-9, whether galectin-9 can act via other
receptors [70], or whether there are differences in comole-
cules, costimulators, or cosuppressors yet to be described.
The induction of apoptosis by galectin-9 is through the cal-
cium-calpain-caspase-1 pathway; that is, cytochrome c is
released from mitochondria and caspase-activated [71].
Galectin-9 expression in intestine epithelial cells is upreg-
ulated in the intestine in patients with food allergy. Mast cells
stimulate galectin-9 expression by secreting tryptase, which
in turn activate the proteinase-activated receptor 2 on the
epithelial cells. Secreted galectin-9 will in turn activate
dendritic cells [72]. In another mucosal surface, the airways,
administered galectin-9 inhibited airway hyperresponsive-
ness and by binding to CD44 and inhibited hyaluronan
attachment; galectin-9 inhibited Th2-associated inflamma-
tion in the airways [73].
As explained above, galectin-9 binds TIM3, a marker
present on many immune cells. In early preeclampsia,
peripheral lymphocytes, T-cells, cytotoxic T-cells, NK cells,
and CD56dim NK cells have reduced TIM3 levels, and an
increased frequency of lymphocytic cells with positive
galectin-9 expression is found. The lowered TIM3 levels
could mean that the normal role of TIM3/galectin-9 in
suppressing Th1 cells and secretion of IFN-γ and inducing
apoptosis is compromised. One possible explanation is that
galectin-9 cannot inhibit inflammation in a situation where
TIM3 is downregulated [74]. In the maternal fetal interface,
natural killer cells are involved in maternal tolerance of the
fetus; the TIM-3/galectin-9 pathway is key to upholding the
local tolerance by suppressing a unique NK cell subset’s cyto-
toxicity toward trophoblasts [75]. These decidual NK cells
are CD56-positive and CD16-negative cells that are impor-
tant in immunomodulation in implantation and pregnancy
[76]. The cytotoxic activity of decidual NK cells can be
switched on; however, this is suppressed in normal pregnan-
cies. Women with recurrent spontaneous abortion have an
increased number of cytotoxic NK cells in the endometrium
[77]. Interestingly, TIM3 inhibits degranulation of NK cells,
and hence cytotoxicity toward trophoblasts, in a galectin-9-
dependent way [75].
Galectin-9 is present in intestinal epithelial cells in low
amount; however, the levels increase in patients with food
allergy. Blocking galectin-9 in a mouse food allergy model
inhibited the allergenic hypersensitivity status and Th2
polarization [72].
Galectin-9 is also expressed in adipose tissues, and in
diet-induced obesity in mice, subcutaneous adipose tissue
showed increased galectin-9 expression. Increased galectin-
9 expression was also observed in both CD11c− and
CD11c+ macrophages in visceral adipose tissue compared
to lean mice [13]. Galectin-9 is suggested to downregulate
inflammation by modulating the interaction of macrophages
with T lymphocytes via TIM3.
During obesity, fat can build up in the liver with nonalco-
holic fatty liver disease as a result. The disease development is
depending upon natural killer cells positive for TIM3; these
cells will go into apoptosis when stimulated by galectin-9.
Even if galectin-9 can also stimulate natural killer cell prolif-
eration by increasing TIM3+ Kupffer cells’ secretion of IL-15,
exogenous administration of galectin-9 decreases the devel-
opment of nonalcoholic fatty liver disease [78]. Similar
results are also found in obesity-induced diabetes where a
Th1 inflammation response is involved in development of
diabetes. In mice, galectin-9, upregulated by injection of plas-
mid encoding galectin-9, inhibits the development of diabe-
tes. This probably takes place through binding to TIM3,
and galectin-9/TIM3 interacting reduced Th1 cell numbers
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in the spleen, pancreatic lymph node, and pancreas [79].
Galectin-9 could thus be a possible target for therapeutic
strategies to reduce inflammation in obese atients to reduce
diseases such as diabetes and fatty liver.
2.8. Galectin-10/Charcot-Leyden Crystal Protein. Galectin-10
is a prototype galectin present as dimers. When eosinophils
are recruited to an inflamed site, they are observed to contain
autocrystallizing Charcot-Leyden crystal protein, also named
galectin-10. When eosinophils degranulate, the galectin-10
crystal deposited can stay in the tissues, in among others
asthmatic patients, for extended periods of time. These
crystals can induce inflammation in acute peritonitis and
bronchitis [80]. Galectin-10 is present in large amounts in
eosinophils and basophils, making up 7–10% of the total
protein of eosinophils [81]. Galectin-10 is also expressed in
CD4+CD25+ regulatory T-cells [82]; these T-cells are impor-
tant in downregulation of antiself responses. Interestingly,
inhibiting galectin-10 in activated CD25+ Treg cells restored
Treg cell proliferative capacity and also overrode their sup-
pressive function [82]. A subpopulation of eosinophils are
regulatory eosinophils that can suppress T-cells, through a
mechanism that are partly dependent upon galectin-10
[83]. Extracellular recombinant galectin-10 can also suppress
T-cell proliferation [83]. Galectin-10 could be a human-
specific galectin as it has not been found in other mammals
[84]. For galectin-10, there is a need for more information
on its molecular role in immunology. A recent study showed
induction of IL-1β release upon Charcot-Leyden crystals/
galectin-10 uptake by primary human macrophages. The
IL-1β release was dependent upon activation of the NLRP3
inflammasome [80]. This indicates a key role for galectin-
10 in inflammation, and further studies in this field hold a
potential for novel new treatments of inflammation-
dependent diseases.
2.9. Galectin-12. Galectin-12 is a tandem galectin with two
CRDs where the C-terminal CRD has less homology with
classic CRDs than the N-terminal CRD has; the latter has
the classical lectin fold with two beta-sheets [85]. Galectin-
12 is predominantly expressed in adipose tissue [86].
Differentiation of 3T3-L1 cells into adipocytes is inhib-
ited by downregulation of galectin-12, and upregulation of
galectin-12 induces G1 cell cycle arrest and apoptosis [87].
This suggests that galectin-12 has a central role in adipocyte
turnover. Allyl isothiocyanate (AITC) reduced the expression
of galectin-12 and could reduce the body weight of high-fat-
diet-fed mice, further reducing the accumulation of lipid
droplets in the liver, and white adipocyte size [88]. On the
other hand, a restriction in calories fed increased galectin-
12 mRNA levels and treatment of obese animals with trogli-
tazone, a thiazolidinedione, increased galectin-12 expression
and decreased adipose tissue size [86]. Hence, both reduced
and increased expressions of galectin-12 decrease adipocyte
size. The adipose tissues are key in the balance between
triglyceride synthesis during energy surplus and lipolysis
during energy needs. Interestingly, galectin-12 has a role in
upholding this balance, and ablation of galectin-12 in mice
shows that galectin-12 has a profound effect on lipid turnover
and its removal induces lipolysis and decreases adiposity
[89]. Galectin-12 is localised to lipid droplets where it
inhibits lipolysis. The binding of galectin-12 to other
molecules is probably not through the classical N-terminal
CRD, as lactose does not influence the binding; however,
the C-terminal nonclassical CRD is postulated to have less
affinity for lactose [85] and could be involved in still-to-be-
characterised ligand binding. An increase in lipolysis was
not found in the liver and muscle in galectin-12-negative
mice. This is not surprising as the main localisation of
galectin-12 is in the adipose tissues [89]. Galectin-12 is inhi-
biting phosphorylation-dependent recruitment of hormone-
sensitive lipase to lipid droplets probably by restricting the
amount of the second messenger cAMP, and galectin-12-
negative mice show increased phosphorylation of hormone-
sensitive lipase by protein kinase A activated by cAMP.
Galectin-12-deficient obese mice also show less insulin
resistance/glucose intolerance than do wild-type obese mice
so the insulin sensitivity and the glucose tolerance are
increased [89]. Hence, galectin-12 is a possible target for
therapies to reduce obesity and diabetes mellitus (type 2).
Galectin-12 in the adipose tissues is also important for the
inflammation state of the tissue as galectin-12 promotes
inflammation [90].
Galectin-12 is expressed in macrophages, in addition to
adipose tissues [90]. Interestingly, macrophages are infiltrat-
ing adipose tissues in obesity [11]. In adipose tissues of mice
with diet-induced obesity, there is an increase in macro-
phages observed in adipose tissues before there is a substan-
tial increase in insulin levels characteristic for systematic
insulin resistance [12]. This increase in macrophages is not
observed in the muscle, liver, lung, and spleen until very late
(after 26 weeks on a high-fat diet) where macrophage gene
CD68 was expressed in the liver [12]. It is suggested that
the abnormal fat metabolism caused by the increasing adi-
posity is causing the macrophage accumulation [12]. The
macrophages in the adipose tissues could release cytokines
that lessen macrophage insulin sensitivity, which again
would stimulate recruitment of more macrophages due to
the metabolic changes [12]. The macrophages in adipose
tissues are heterogenic. Classical M1 macrophages are proin-
flammatory, and the alternatively activated, M2macrophages
are anti-inflammatory. The proinflammatory macrophages
are associated with insulin resistance [11]. In the liver,
activation of Kupffer cells by the alternative activation path-
way via the peroxisome proliferator-activated receptor delta
counteracts obesity-induced insulin resistance [91]. Galec-
tin-12−/− macrophages showed lower phagocytosis of E. coli
than did galectin-12+/+ macrophages, and galectin-12−/− also
promoted a M2 macrophage profile during macrophage
activation [90] suggesting reduced inflammation when
galectin-12 is not present. This is supported by the fact that
galectin-12-negative mice fed a high-fat diet had less macro-
phage infiltrations into adipose tissue than control mice had,
as well as lower cholesterol and triglyceride in serum [90].
Galectin-12 expression is linked to galectin-3 expression,
and knockout of galectin-3 reduces adipose tissue expres-
sion of galectin-12 [92]. This suggests that galectin-3
inhibitors could not only target galectin-3 but also lead
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to reduced galectin-12 levels and hence decreased adipose
inflammation. However, inhibition of galectin-12 will not
change galectin-3 levels [90]; hence, targeting galectin-12
will not clinically help reduce galectin-3 effects.
2.10. Galectin-13, Galectin-14, and Galectin-16. Galectin-13,
-14, and -16 were suggested to have placenta-specific expres-
sion predominantly in the syncytiotrophoblast, a primary site
of metabolic exchange [93], and they are suggested to be
important for pregnancy tolerance development. Galectin-
13 is special in that the monomers in the homodimer are
covalently linked by disulphide bonds [94] whilst other galec-
tins interact noncovalently. Low galectin-13 levels in the
third trimester are strongly correlated with preeclampsia
[95], and low levels of galectin-13 expression in week 11 were
observed in trophoblasts from residual samples of chorionic
villus in women who later developed preeclampsia [96].
Galectin-13 can, as galectin-1, -3, and -9, induce apoptosis
of activated T-cells, and it is suggested that this could be
important to hinder maternal immune cells in attacking
the fetus [93].
The extravillous trophoblast from the cervix of early
pregnancy loss patients had a reduced level of galectin-14
[97, 98]; also, downregulation of galectin-14 has been found
in preterm severe preeclampsia [15].
Galectin-13, -14, and -16 can induce apoptosis of T-cells
important in the placenta [93].
The placental localisation of these galectins suggests they
are not important for obesity-developed inflammation prob-
lems in the adult.
2.11. Clinical Potential of Galectins. Galectins have major
roles in processes as diverse as cancer, obesity, diabetes, pre-
eclampsia, and cardiovascular disease. Human galectin-1, -2,
-3, -4, -7, -8, -9, and -12 are all interesting in an immunolog-
ical perspective as they can induce T-cell apoptosis and mod-
ulate inflammation. This review has focused on the role of
galectins in inflammation and metabolism, and in this per-
spective, the current knowledge points to galectin-1, -2, -3,
-9, and -12 as especially interesting. For galectin-1 and galec-
tin-9, an increase in the levels of the proteins could protect
against diabetes, whilst for galectin-12 inhibition of the pro-
tein could be protective. In the case of galectin-3, the data
are not as straightforward. In the case of galectin-2, we did
not find diabetes or obesity-related studies, but galectin-2
modulates inflammation and its presence in the pancreas is
interesting and its role in inflammation in the pancreas could
be further studied.
In principle, there is hence a potential to treat diseases
and disorders by inhibiting some galectins; for others, direct
administration of galectin on surfaces or by injections could
be beneficial, and for both groups, targeted decrease or
increase, respectively, of the expression of the proteins could
be therapeutic. The fact that galectins are involved in numer-
ous cellular and intracellular processes, and the fact that there
is conserved sequence homology between the galectins, could
complicate treatment strategies. However, increased knowl-
edge on galectins’ site-specific functions, posttranslational
modifications, and binding partners could make it possible
to construct modified recombinant galectins as well as spe-
cific inhibitors [99]. To increase inhibitor specificity, work
on designing new inhibitors and studying the inhibitors’
interactions with different galectins [100] is important
and promising.
Proof of concept of galectin inhibition and the use
of administered galectin as treatments come from ani-
mal experiments described for the individual galectins
above and in this section, and in a limited amount from
clinical trials.
Intraperitoneal injection of galectin-1 prevents onset of
hyperglycemia and reverse pancreatic beta cell autoimmunity
in the pancreas in mice [101]. In addition, healing of patho-
logical wounds in diabetic mice was accelerated by subcuta-
neous injection of galectin-1 [102]. Galectin-1 is implicated
in tumor development [3] and in obesity [22, 23], and the
galectin-1 inhibitor thiodigalactoside reduced the body
weight gain in mice [23].
We did not find clinical studies in human targeting
galectin-1 by the use of inhibitors or injections of the protein.
However, a study using bevacizumab (antibody against vas-
cular endothelial growth factor) and ipilimumab (antibody
against cytotoxic T-lymphocyte-associated antigen 4) on
patients with metastatic melanoma found that patients with
therapeutic responses made antibodies against galectin-1,
whilst a group of patients with reduced survival had
increased circulating galectin-1 protein levels [103]. There
is a wide interest in galectin-1 as a possible therapeutic target,
and inhibitors of galectin-1, modified galectin-1, antibodies
against galectin-1, and strategies for targeted delivery are cur-
rently investigated, and several companies, universities, and
institutes hold patents for the use of these potential treatment
strategies (thoroughly reviewed in [99]). Since both adminis-
tration of galectin-1 and inhibition of it can be beneficial,
studies need to be holistic and body weight, diabetes, and
cancer should be monitored in further work.
Galectin-3 is a complex therapeutic target as it is involved
in both inhibition and stimulation of inflammation. Treat-
ment targeting galectin-3 must also take into consideration
the fact that galectin-3 promotes cancer and metastasis [1]
and that there is not a causal necessity between a protein
being upregulated in a disease and the possibility to treat
the disease by inhibiting the protein. This is clearly shown
in a transgenic fibrotic cardiomyopathy model in mice,
where galectin-3 was upregulated both at mRNA and protein
levels; however, neither galectin-3 inhibitors nor galectin-3
knockout were effective in reversing cardiac fibrosis or
inflammation [104]. This suggests that in fibrotic cardiomy-
opathy, at least in this mouse model, galectin-3 increase is a
symptom, not an inducer of the disease. In a heart failure
model in mice, however, proposed inhibition of galectin-3
with modified citrus pectin reduced myocardial inflamma-
tion, and reversed isoproterenol induced fibrogenesis that,
untreated, led to left ventricular dysfunction [105]. It should
be noted that even though pectins inhibit galectin-3-induced
hemagglutination and cell interaction [106], a thorough
in vitro study of plant-derived polysaccharides, including
pectin, showed low inhibition or no inhibition at all of
galectin-3 [107]. Therefore, the reduced myocardial
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inflammation effects of citrus pectin could be through other
mechanisms than direct galectin-3 inhibition.
There are several inhibitors targeting galectin-3 (reviewed
with a focus on patents in [108]). In humans, there are a few
studies targeting galectin-3. The galectin-3 inhibitor GR-
MD-02 (galactoarabino-rhamnogalacturonate; it also binds
galectin-1 but with lower affinity) was used in a double-
blinded study on subjects with nonalcoholic steatohepatitis
with advanced fibrosis. The highest dose tested reduced
fibrosis [109]. The same drug was used to study potential
inhibition of inflammation in psoriasis subjects (only five
subjects and no control group). Interestingly, patients infused
with GR-MD-02 biweekly 13 times showed an average of
>50% reduction in the Psoriasis Area Severity Index [110].
However, the lack of control subjects, the few subjects
included, and the short time frame studied suggest that fur-
ther studies must be conducted before one can conclude that
the galectin-3 inhibitor has potential for treating psoriasis.
Galectin-9 promotes apoptosis of several cell types,
including T-cells, in a TIM3-dependent manner [70] and
hence modulates inflammation. In development of type 1
diabetes, insulin-producing beta cells in the pancreas are
destroyed; this autoimmune destruction is dependent on
Th1 cells. Interestingly, upregulation of galectin-9 by injec-
tion of a galectin-9 plasmid in mice significantly protected
them from diabetes [79]. In another mouse study, injection
of galectin-9 inhibited development of diabetes, and an anti-
body against TIM3 was at least as effective as galectin-9 injec-
tions in protecting against development of diabetes [111].
This strongly suggests that galectin-9 and molecules interact-
ing with it such as TIM3 have key roles in diabetes and have a
therapeutic potential. A study using prebiotic galacto-
oligosaccharides and fructooligosaccharides in combination
with Bifidobacterium breve M-16V increased serum and
intestinal epithelial cell levels of galectin-9 in mice [112].
Infants with atopic dermatitis in a double-blind, placebo-
controlled study fed a hydrolysed formula without (control)
or with galactooligosaccharides and fructooligosaccharides
in combination with Bifidobacterium breve for twelve weeks
had reduced allergic symptoms [113]. This correlated with
increased galectin-9 levels in serum [112]. This indicates that
it is possible to increase galectin-9 by dietary administration
of pre- and probiotica. However, in a human study, it was not
possible to conclude whether galectin-9 levels were protective
or promoting for the progression of diabetic nephropathy
[114]. Hence, additional studies on galectin-9 and diabetes
are needed to see if injection of galectin-9 can prevent diabe-
tes also in human and if the side effects are acceptable.
Galectin-12 was identified in 2001 and is interesting
since it is expressed in adipocytes [85, 86]. There are few
galectin-12 studies, but importantly galectin-12-negative
mice (Lgals12−/−) [89] have increased lipolysis, adipocyte
mitochondrial respiration, reduced whole body lipid con-
tent, increased insulin sensitivity compared to wild-type
(Lgals12+/+) mice. Targeting galectin-12 is interesting as
it is fat tissue specific and therefore targeting it could help
in the prevention/treatment of obesity and diabetes in a
targeted manner where other processes, such as cancer,
maybe are not affected.
3. Conclusions
This review shows that several galectins are key regulators of
inflammation in general and that some galectins are involved
in the regulation of inflammation processes in obesity leading
to, among others, diabetes. Given their important regulatory
roles, they are appealing targets for treatment of human
diseases. However, limited human studies targeting galectins
are available. It is therefore clear that more research is needed
to target individual galectins with specificity, in a timely
manner and in specific tissues and cells.
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